Rapid regression of retinal hemorrhage and neovascularization in a case of familial exudative vitreoretinopathy treated with intravitreal bevacizumab

Graefes Arch Clin Exp Ophthalmol. 2008 Dec;246(12):1787-9. doi: 10.1007/s00417-008-0949-6. Epub 2008 Sep 16.

Abstract

Purpose: To report a case of familial exudative vitreoretinopathy (FEVR) rapidly resolved by intravitreal injection of bevacizumab.

Methods: A 36-year-old woman complained about floaters and visual field defect. Funduscopic examinations revealed retinal vessel anastomosis located between the equator and ora serrata in both eyes. The right eye was accompanied with slight vitreous hemorrhage. Since the patient declined retinal cryopexy for cosmetic reasons, intravitreal bevacizumab injections (1.25 mg/0.05 ml) were performed in both eyes.

Results: Treatment resulted in the rapid regression and the accelerated fibrosis of neovascular tissues. At 4-month follow-up in the right eye and 1-month follow-up in the left, no signs of systemic or ocular complications were detected.

Conclusions: Intravitreal injection of bevacizumab may be considered as an alternative method in treating FEVR.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Angiogenesis Inhibitors / administration & dosage*
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Exudates and Transudates / metabolism
  • Eye Diseases / complications
  • Eye Diseases / drug therapy*
  • Eye Diseases / genetics
  • Eye Diseases / metabolism
  • Female
  • Fundus Oculi
  • Humans
  • Injections
  • Neovascularization, Pathologic / etiology*
  • Neovascularization, Pathologic / pathology
  • Remission Induction
  • Retinal Diseases / complications
  • Retinal Diseases / drug therapy*
  • Retinal Diseases / genetics
  • Retinal Diseases / metabolism
  • Retinal Hemorrhage / etiology*
  • Retinal Hemorrhage / pathology
  • Retinal Vessels*
  • Time Factors
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Vitreous Body*

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Vascular Endothelial Growth Factor A
  • Bevacizumab